Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC

ClinicalTrials.gov ID: NCT06745882

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT06745882. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:41 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Prospective Trial to Assess Real-world Outcomes and Predictive Biomarkers of Response to Pembrolizumab With or Without Chemotherapy in Black Patients With NSCLC

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a non-registrational, cohort study enrolling eligible Black patients diagnosed with histologically or cytologically, advanced/metastatic NSCLC without known EGFR/ALK/ROS1 tumor mutations, and who are ≥ 18 years of age, ECOG performance status 0-2, and may have detectable ctDNA at baseline.

Study identification

NCT ID: NCT06745882
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Enrollment: 318 participants

Conditions and interventions

Conditions

Non-small Cell Lung Cancer

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 13, 2025 (Actual)
Primary completion: Jan 2030 (Estimated)
Completion: Jan 2030 (Estimated)
Last update posted: Sep 21, 2026

2025 – 2030

United States locations

U.S. sites: 11
U.S. states: 6
U.S. cities: 8

Facility	City	State	ZIP	Site status
Moffitt Cancer Center	Tampa	Florida	33612	Recruiting
Our Lady of the Lake Physician's Group	Baton Rouge	Louisiana	70805	Recruiting
University of Maryland Greenebaum Cancer Center	Baltimore	Maryland	21201	Recruiting
Sinai Hospital of Baltimore	Baltimore	Maryland	21215	Recruiting
Medstar Franklin Square	Baltimore	Maryland	21237	Recruiting
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center	Baltimore	Maryland	21287	Recruiting
TidalHealth Peninsula Regional	Salisbury	Maryland	20801	Recruiting
Montefiore Medical Cancer Center	The Bronx	New York	10461	Recruiting
FirstHealth of the Carolinas, Inc.	Pinehurst	North Carolina	28374	Recruiting
Baptist Clinical Research Institute	Memphis	Tennessee	38120	Recruiting
Nashville General Hospital	Nashville	Tennessee	37208	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06745882, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 21, 2026 · Synced Nov 15, 2026